Surgery vs. Radical Chemoradiotherapy for Esophageal SCC After Neoadjuvant Immunochemotherapy (HCHTOG2603)
A Multicenter, Open-Label, Randomized Controlled Phase III Clinical Trial Comparing Surgery Versus Radical Chemoradiotherapy (Organ Preservation) in Patients With Thoracic Esophageal Squamous Cell Carcinoma Achieving cCR or cPR Following Neoadjuvant Immunochemotherapy
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 3
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Yan Zheng, M.D./Ph.D
- Telefonnummer: (+86)0371-65587610
- E-mail: hnszlyylixiang@163.com
Undersøgelse Kontakt Backup
- Navn: Song
- Telefonnummer: (+86)0371-65587610
- E-mail: hnszlyylixiang@163.com
Studiesteder
-
-
Henan
-
Zhengzhou, Henan, Kina, 450008
- Rekruttering
- Henan Cancer Hospital
-
Kontakt:
- Yan Zheng, M.D./Ph.D
- Telefonnummer: +86-371-65587610
- E-mail: hnszlyylixiang@163.com
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
- Age 18-75 years, any sex.
- ECOG Performance Status 0-1.
- Histologically confirmed, previously untreated thoracic esophageal squamous cell carcinoma (ESCC).
- Clinical stage cT2N0M0, T3N0-2M0 (AJCC 8th Edition), assessed as resectable with a potential for R0 resection by endoscopic ultrasound (EUS), PET-CT, and contrast-enhanced CT. Patients with cervical lymph node metastasis may also be included if deemed suitable for three-field lymphadenectomy by a multidisciplinary team assessment.
Adequate bone marrow, hepatic, and renal function:
- Absolute neutrophil count ≥ 1.5 × 10⁹/L, Platelet count ≥ 100 × 10⁹/L, Hemoglobin ≥ 90 g/L.
- Alanine aminotransferase / Aspartate aminotransferase ≤ 2.5 × Upper Limit of Normal, Total bilirubin ≤ 1.5 × Upper Limit of Normal.
- Serum creatinine ≤ 1.5 × Upper Limit of Normal or Creatinine clearance ≥ 60 mL/min.
- Signed written informed consent form (ICF).
Exclusion Criteria:
- History of other malignancy within the past 5 years.
- Active autoimmune disease.
- Active Hepatitis B Virus (HBV) / Hepatitis C Virus (HCV) / Human Immunodeficiency Virus (HIV) infection.
- Severe cardiac or pulmonary insufficiency (Left Ventricular Ejection Fraction < 50%, Forced Expiratory Volume in 1 second < 1 L).
- Pregnancy or lactation.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Organ Preservation with Radical Chemoradiotherapy
Patients achieving clinical complete or partial response (cCR/cPR) after neoadjuvant immunochemotherapy will receive definitive chemoradiotherapy for organ preservation.
Radiotherapy (50.4 Gy/28 fractions, IMRT) with concurrent weekly chemotherapy (e.g., paclitaxel + cisplatin).
Patients with ycCR after chemoradiotherapy will enter observation.
Patients with residual disease will undergo salvage esophagectomy.
|
This is the standard induction therapy administered to all enrolled patients.
It consists of the PD-1 inhibitor Toripalimab combined with Nab-paclitaxel
Chemotherapy administered concurrently with radiotherapy
|
|
Eksperimentel: Immediate Esophagectomy
Patients achieving cCR/cPR after neoadjuvant immunochemotherapy will undergo immediate radical esophagectomy (McKeown or Ivor-Lewis procedure) with 2-field or 3-field lymph node dissection.
Postoperative immunotherapy (up to 8 cycles) may be administered based on pathological findings (ypT≥1 or N+).
|
This is the standard induction therapy administered to all enrolled patients.
It consists of the PD-1 inhibitor Toripalimab combined with Nab-paclitaxel
Standard surgical procedure with lymph node dissection
|
|
Aktiv komparator: Non-Responder Surgery
Patients with stable disease (cSD) or progressive disease (cPD) after neoadjuvant immunochemotherapy will undergo immediate radical esophagectomy, which is the standard of care for this subgroup.
Postoperative treatment is determined by pathological findings.
|
This is the standard induction therapy administered to all enrolled patients.
It consists of the PD-1 inhibitor Toripalimab combined with Nab-paclitaxel
Standard surgical procedure with lymph node dissection
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
3-year Event-Free Survival (EFS) Rate
Tidsramme: 3 years after randomization/treatment initiation
|
Event-Free Survival is defined as the time from randomization (for responders) or from the start of neoadjuvant therapy (for the overall population) until the occurrence of any of the following events: Local recurrence of esophageal cancer. Distant metastasis. Death from any cause |
3 years after randomization/treatment initiation
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Neoplasmer efter sted
- Neoplasmer
- Neoplasmer efter histologisk type
- Gastrointestinale neoplasmer
- Neoplasmer i fordøjelsessystemet
- Sygdomme i fordøjelsessystemet
- Gastrointestinale sygdomme
- Neoplasmer i hoved og hals
- Neoplasmer, kirtel og epitel
- Esophageale sygdomme
- Karcinom
- Neoplasmer, pladecelle
- Karcinom, pladecelle
- Esophageale neoplasmer
- Esophageal pladecellekarcinom
- Fysiske fænomener
- Uorganiske kemikalier
- Platinforbindelser
- Stråling
- Toripalimab
- 130-nm albuminbundet paclitaxel
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 2026-150
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .